These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Capizzi RL Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255 [TBL] [Abstract][Full Text] [Related]
3. Future development of amifostine as a radioprotectant. Werner-Wasik M Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272 [TBL] [Abstract][Full Text] [Related]
5. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine. Mehta MP Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996 [TBL] [Abstract][Full Text] [Related]
6. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects. Peters GJ; van der Vijgh WJ Eur J Cancer; 1995; 31A Suppl 1():S1-7. PubMed ID: 7577093 [TBL] [Abstract][Full Text] [Related]
7. Amifostine modulation of bleomycin-induced lung injury in rodents. Nici L; Calabresi P Semin Oncol; 1999 Apr; 26(2 Suppl 7):28-33. PubMed ID: 10348257 [TBL] [Abstract][Full Text] [Related]
8. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. van der Vijgh WJ; Peters GJ Semin Oncol; 1994 Oct; 21(5 Suppl 11):2-7. PubMed ID: 7973774 [TBL] [Abstract][Full Text] [Related]
9. Administration of the cytoprotectant amifostine. Lindemann K Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150 [TBL] [Abstract][Full Text] [Related]
10. Amifostine in clinical oncology: current use and future applications. Koukourakis MI Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063 [TBL] [Abstract][Full Text] [Related]